Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2017 Mar 3;8:219. doi: 10.3389/fimmu.2017.00219

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2017 Alvarez Salazar, Cortés-Hernández, Alemán-Muench, Alberú, Rodríguez-Aguilera, Recillas-Targa, Chagoya de Sánchez, Cuevas, Mancilla-Urrea, Pérez García, Mondragón-Ramírez, Vilatobá, Bostock, Hernández-Méndez, De Rungs, García-Zepeda and Soldevila.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

FOXP3 expression is reduced in regulatory T cells (Tregs) from BLT-treated patients independently of Helios expression. (A) No differences in the frequency of Helios⁺ on Tregs population from the three evaluated groups. (B) Reduced expression of FOXP3 within Helios⁺ (left panel) or Helios⁻ Tregs (right panel) of transplanted patients (BLT = 19 and CsA = 7) compared with control group (n = 9). (C) CD25 expression was significantly reduced in Helios⁻ but not in Helios⁺ Tregs from BLT patients. Statistical analysis was performed using non-parametric Mann–Whitney test, two tailed. BLT, belatacept; CsA, Cyclosporine A. Control group was composed by healthy individuals.